Show simple item record

dc.contributor.authorKwegyir-Afful, A.K.
dc.contributor.authorRamalingam, S.
dc.contributor.authorRamamurthy, V.P.
dc.contributor.authorPurushottamachar, P.
dc.contributor.authorMurigi, F.N.
dc.contributor.authorHuang, W.
dc.contributor.authorKane, M.A.
dc.contributor.authorZhang, Y.
dc.contributor.authorAmbulos, N.
dc.contributor.authorHussain, A.
dc.contributor.authorQiu, Y.
dc.contributor.authorWeber, D.J.
dc.contributor.authorNjar, V.C.O.
dc.date.accessioned2019-11-12T20:30:55Z
dc.date.available2019-11-12T20:30:55Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85074236077&doi=10.3390%2fcancers11111637&partnerID=40&md5=d6d56eec5f73a53010597c442932d471
dc.identifier.urihttp://hdl.handle.net/10713/11404
dc.description.abstractThese studies compared the efficacies of our clinical agent galeterone (Gal) and the FDA-approved prostate cancer drug, enzalutamide (ENZ) with two lead next generation galeterone analogs (NGGAs), VNPP414 and VNPP433-3β, using prostate cancer (PC) in vitro and in vivo models. Antitumor activities of orally administered agents were also assessed in CWR22Rv1 tumor-bearing mice. We demonstrated that Gal and NGGAs degraded AR/AR-V7 and Mnk1/2; blocked cell cycle progression and proliferation of human PC cells; induced apoptosis; inhibited cell migration, invasion, and putative stem cell markers; and reversed the expression of epithelial-to-mesenchymal transition (EMT). In addition, Gal/NGGAs (alone or in combination) also inhibited the growth of ENZ-, docetaxel-, and mitoxantrone-resistant human PC cell lines. The NGGAs exhibited improved pharmacokinetic profiles over Gal in mice. Importantly, in vivo testing showed that VNPP433-3β (at 7.53-fold lower equimolar dose than Gal) markedly suppressed (84% vs. Gal, 47%; p < 0.01) the growth of castration-resistant PC (CRPC) CWR22Rv1 xenograft tumors, with no apparent host toxicity. ENZ was ineffective in this CRPC xenograft model. In summary, our findings show that targeting AR/AR-V7 and Mnk1/2 for degradation represents an effective therapeutic strategy for PC/CRPC treatment and supports further development of VNPP433-3β towards clinical investigation. Copyright 2019 by the authors.en_US
dc.description.sponsorshipThis work was supported in part by a grant from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) (R01CA224696), start-up funds from University of Maryland School of Medicine (UMSOM) and the Center for Biomolecular Therapeutics (CBT), Baltimore, MD, USA to V.C.O.N., Merit Review Award (101 BX000545) Medical Research Service, Department of Veterans Affairs to A.H., NIH (R01CA106504) and VA (I01 BX004160/BX/BLRD) to Y.Q. and Marlene and Stewart Greenebaum Comprehensive Cancer Center (MSGCCC; Philanthropic Funds), Baltimore, MD, USA to A.H., Y.Q. and V.C.O.N.en_US
dc.description.urihttps://doi.org/10.3390/cancers11111637en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofCancers
dc.subjectApoptosisen_US
dc.subjectCastration-/drug-resistant PC cellen_US
dc.subjectGaleterone (Gal)en_US
dc.subjectMnk-eIF4E/mTORC1 Signaling pathwaysen_US
dc.subjectMnk1/2 degradersen_US
dc.subjectNGGAsen_US
dc.subjectProstate canceren_US
dc.subjectVNPP433-3β AR/AR-V7en_US
dc.titleGaleterone and the next generation galeterone analogs, VNPP414 and VNPP433-3β exert potent therapeutic effects in castration-/drug-resistant prostate cancer preclinical models in vitro and in vivoen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/cancers11111637


This item appears in the following Collection(s)

Show simple item record